Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River announced a Research Collaboration Agreement with the FDA and Labcorp to develop sensitive screening tools for quantifying and ranking the abuse potential of new drugs, including abuse-deterrent formulations. The collaboration may inform regulatory assessments under the Controlled Substances Act and leverages behavioral economic models of supply and demand, with a pilot at Charles River's Mattawan site providing proof-of-concept data.
Key figures
- Fda approved products assessed
- 15
- Abuse potential studies conducted
- over 100
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.